Document is current

Article History

Received: 29 October 2021

Accepted: 25 October 2022

First Online: 13 December 2022

Declarations

:

: The study was approved by the Institutional Review Board (IRB) at the University of Alabama at Birmingham (UAB, 300002272; UAB Coordinating Center 300002554). All investigations were conducted in conformity with ethical principles of research.Each interview began with a verbal informed consent of the potential benefits and risks of participating in the study and their rights as participants in the study. The IRB approved the use of verbal informed consent given that the interviews were conducted via telephone. During the consent process, clinic staff were informed that participation was voluntary, and they could withdraw from the study at any time.

: Not applicable.

: There are no financial conflicts related directly to this study. JS has received consultant fees from Crealta/Horizon, Medisys, Fidia, PK Med, Two labs Inc., Adept Field Solutions, Clinical Care options, Clearview healthcare partners, Putnam associates, Focus forward, Navigant consulting, Spherix, MedIQ, Jupiter Life Science, UBM LLC, Trio Health, Medscape, WebMD, and Practice Point communications; and the National Institutes of Health and the American College of Rheumatology. JS owns stock options in TPT Global Tech, Vaxart pharmaceuticals and Charlotte’s Web Holdings, Inc. JS previously owned stock options in Amarin, Viking and Moderna pharmaceuticals. JS is on the speaker’s bureau of Simply Speaking. JS is a member of the executive of Outcomes Measures in Rheumatology (OMERACT), an organization that develops outcome measures in rheumatology and receives arms-length funding from 8 companies. JS serves on the FDA Arthritis Advisory Committee. JS is the chair of the Veterans Affairs Rheumatology Field Advisory Committee. JS is the editor and the Director of the University of Alabama at Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JS previously served as a member of the following committees: member, the American College of Rheumatology’s (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee.All authors declare that they have no competing interests.